Related Experiment Video

Updated: Apr 16, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K

Managing advanced prostate cancer: the rapidly changing treatment landscape

Robert Dreicer1

  • 1Dreicer@ccf.org.

The American Journal of Managed Care
|March 4, 2015
PubMed

Insights

Five novel therapies for metastatic castration-resistant prostate cancer offer survival benefits. These include a cancer vaccine, alpha emitter, novel hormonal agents, and a taxane, presenting new treatment challenges due to prostate cancer heterogeneity.

Area of Science:

  • Oncology
  • Medical Therapeutics

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) presents a significant therapeutic challenge.
  • Recent years have seen an unprecedented surge in FDA-approved treatments for mCRPC.

Purpose of the Study:

  • To review the recent FDA approvals of novel therapeutic agents for mCRPC.
  • To highlight the diverse mechanisms of action of these new agents.
  • To discuss the emerging challenges in optimizing treatment for heterogeneous mCRPC.

Main Methods:

  • Review of recent FDA approvals for mCRPC.
  • Analysis of the mechanisms of action for newly approved agents.
  • Discussion of clinical implications and challenges in mCRPC management.

Main Results:

  • Five new therapeutic agents approved for mCRPC within four years.
  • Agents include a cancer vaccine, alpha emitter, two novel hormonal therapies, and a taxane.
  • These agents offer potential survival improvements for mCRPC patients.

Conclusions:

  • The rapid approval of diverse mCRPC agents marks a significant advancement in oncology.
  • Optimal utilization of these novel, expensive therapies requires careful consideration of prostate cancer heterogeneity.
  • Further research is needed to guide personalized treatment strategies for mCRPC.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.3K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
853
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K